Repros Therapeutics Inc will abandon efforts to seek approval for its testosterone drug in the United States if an ongoing study fails, and shift focus to its uterine fibroids drug that showed promise in a mid-stage trial.
Repros said on Tuesday its uterine fibroids drug Proellex stopped severe menstrual bleeding in 52 percent of women enrolled in the trial, pushing the company's shares up 175 percent the next day.
The shares continued their climb on Thursday, hitting their highest in five and a half months.
Repros said on Tuesday its uterine fibroids drug Proellex stopped severe menstrual bleeding in 52 percent of women enrolled in the trial, pushing the company's shares up 175 percent the next day.
The shares continued their climb on Thursday, hitting their highest in five and a half months.
